BioPharma Resources

Drug Trial Radar · NCT05804045

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

94

Actual

Start

Apr 27, 2023

Primary completion

Sep 23, 2024

Study completion Jun 2028

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Apr 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: * Whether the Pimicotinib(ABSK021) works well in patients with TGCT. * Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Receive the administration of Pimicotinib(ABSK021) till study end in study part 3. * Complete the study procedures speficied in the protocol, which is guided by researchers.

Conditions

  • Tenosynovial Giant Cell Tumor
  • Pigmented Villonodular Synovitis
  • Giant Cell Tumor of Tendon Sheath

Interventions

  • Pimicotinib(ABSK021)Drug

    capsule

  • PlaceboDrug

    capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Baseline to Week 25

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • Precision NextGen Oncology

    Beverly Hills, California

  • Duke University Medical Center

    Durham, California

  • Henry Ford Health System

    Detroit, Michigan

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • McGill University Health Center

    Montreal, Canada

  • Princess Margaret Cancer Center

    Toronto, Canada

  • Beijing Jishuitan Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

    Enshi, Hubei, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Nanjing Drum Tower hospital

    Nanjing, Jiangsu, China

  • Liaoning Cancer Hospital&Institute

    Shenyang, Liaoning, China

  • Weifang People's Hospital

    Weifang, Shandong, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Xi'an Honghui Hospital

    Xi’an, Shanxi, China

  • West China Hospital Sichuan University

    Chengdu, Wuhan, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • IRCCS Istituto Ortopedico Rizzoli

    Bologna, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Ospedale di Prato

    Prato, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Fundacion Jimenez Diaz

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.